AstraZeneca Pharma India saw a significant boost in its share price, surging by 8% in early trade on September 24. This increase followed the company’s approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab, a cancer treatment solution.
AstraZeneca shares surge after CDSCO clearance
At 09:31 AM, AstraZeneca Pharma's stock was trading at ₹7,320.60 on the Bombay Stock Exchange (BSE), reflecting an 8.51% rise. This jump came after the pharmaceutical giant received clearance to distribute Durvalumab (Imfinzi), a solution for infusion used in cancer therapy.
For those looking to invest in stocks, this approval signals promising developments in AstraZeneca's portfolio, which could attract further investment.
CDSCO approval: A game changer
According to the company’s exchange filing, AstraZeneca received the go-ahead to sell Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solutions in India. Durvalumab, in combination with chemotherapy, is used to treat non-small cell lung cancer (NSCLC) patients without specific genetic mutations.
This approval is expected to enhance AstraZeneca’s oncology offerings and create opportunities for investors wanting to invest in stocks linked to innovative cancer treatments.
New launches on the horizon
In addition to Durvalumab, AstraZeneca is preparing to introduce two other treatments in India by October 2024: Palivizumab (Synagis) and Tremelimumab (Imjudo). Tremelimumab, when used with Durvalumab, is prescribed for patients with unresectable hepatocellular carcinoma, while Palivizumab helps prevent severe respiratory tract infections in children at high risk.
These new launches reflect AstraZeneca's continuous expansion and could be pivotal for those planning to invest in stocks in the pharmaceutical sector.
Stock performance and investor outlook
AstraZeneca’s stock has experienced significant growth, with a 52-week high of ₹7,550 and a low of ₹4,050.15. Despite trading 3.04% below its yearly high, the stock is still up by 60% over the past year, offering substantial returns to investors.
As the company moves forward with new approvals and product launches, those looking to invest in stocks may find this an opportune moment to capitalise on AstraZeneca's momentum.
Why this matters for stock investors
The recent surge in AstraZeneca’s share price underscores the impact of regulatory approvals on stock performance. For investors seeking opportunities in the pharmaceutical sector, this approval represents a strong reason to invest in stocks that have the potential for growth driven by new drug launches.
AstraZeneca’s portfolio, combined with its strategic expansion in India, makes it an attractive option for investors aiming for long-term gains.
By staying ahead in the pharmaceutical race and receiving crucial approvals, AstraZeneca continues to strengthen its position, making it a valuable stock to consider for those eager to invest in stocks in the healthcare industry.
For android only